Episode Details
Back to Episodes
Southampton, UK based Curve Therapeutics believes its mammalian cell-based 'Microcycle' platform is a better way to do drug discovery - lead programs from it target HIF-1/HIF-2 and ATIC
Published 1 year, 2 months ago
Description
Co-Founder and CEO Simon Kerry discusses being in Southampton, and why he belives the 'Microcycle' platform beats screening in traditional well plates for discovery work. Curve currently has cash on hand to take at least one program into the clinic.